Patents by Inventor Pierre van der Bruggen

Pierre van der Bruggen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Isolated peptides which bind to HLA-A24 molecules and uses thereof
    Publication number: 20050249743
    Abstract: Peptides which consist of amino acid sequences found in MAGE-4 bind to HLA-A24 to form T cell epitopes. The therapeutic and diagnostic ramifications of this are the subject of this invention, as are various products obtained in the course of the development of the invention.
    Type: Application
    Filed: January 10, 2005
    Publication date: November 10, 2005
    Inventors: Thierry Boon-Falleur, Pierre Van Der Bruggen
  • Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-6 and uses thereof
    Patent number: 6946289
    Abstract: The invention relates to nucleic acid molecules which code for the tumor rejection antigen precursor MAGE-6. Also disclosed are vectors, cell lines, and so forth, which utilize the nucleic acid molecule, and optionally, molecules coding for human leukocyte antigen HLA-A1. Use of these materials in therapeutic and diagnostic contexts are also a part of the invention.
    Type: Grant
    Filed: May 31, 2000
    Date of Patent: September 20, 2005
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Béatrice Guagler, Benoit van den Eynde, Pierre van der Bruggen, Thierry Boon-Falleur
  • Isolated nucleic acid molecules which encode GAGE genes and uses thereof
    Patent number: 6939707
    Abstract: The invention relates to nucleic acid molecules which encode members of the GAGE family of tumor rejection antigen precursors and their use.
    Type: Grant
    Filed: February 13, 2001
    Date of Patent: September 6, 2005
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pierre van der Bruggen, Benoit Van den Eynde, Olivier DeBacker, Thierry Boon-Falleur
  • Tumor antigens and CTL clones isolated by a novel procedure
    Publication number: 20040185033
    Abstract: The present invention relates to isolation of cytotoxic T lymphocyte (CTL) clones. In particular, the present invention relates to isolated CTL clones that are specific for proteins of the MAGE family. The CTL clones of the present invention have been isolated by successive steps of stimulation and testing of lymphocytes with antigen presenting cells which present antigens derived from different expression systems, e.g., from recombinant Yersinia, recombinant Salmonella, or recombinant viruses. The present invention further relates to antigenic peptides as well as the peptide/HLA complexes which are recognized by the isolated CTL clones.
    Type: Application
    Filed: January 7, 2004
    Publication date: September 23, 2004
    Inventors: Pascal Chaux, Rosalie Luiten, Nathalie Demotte, Marie-Therese Duffour, Christophe Lurquin, Catie Traversari, Vincent Stroobant, Guy R. Cornelis, Thierry Boon-Falleur, Pierre van der Bruggen, Erwin Schultz, Guy Warnier
  • MAGE peptides presented by HLA class II molecules
    Publication number: 20040077045
    Abstract: The invention describes HLA class II binding peptides encoded by the MAGE tumor associated genes, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of MAGE genes.
    Type: Application
    Filed: May 23, 2003
    Publication date: April 22, 2004
    Inventors: Yi Zhang, Pascal Chaux, Thierry Boon-Falleur, Pierre Van Der Bruggen
  • Tumor antigens and CTL clones isolated by a novel procedure
    Patent number: 6710172
    Abstract: The present invention relates to nucleic acid molecules encoding antigenic peptides from MAGE molecules that bind to HLA. An example of the nucleic acid molecules of the present invention is a nucleic acid molecule coding for the peptide GVYDGREHTV (SEQ ID NO: 44), which peptide binds to HLA-A2. The nucleic acid molecules and the encoded antigenic peptides are useful for diagnosing and treating various pathological conditions.
    Type: Grant
    Filed: July 30, 2001
    Date of Patent: March 23, 2004
    Assignee: Ludwig Institute For Cancer Research
    Inventors: Pascal Chaux, Rosalie Luiten, Nathalie Demotte, Marie-Therese Duffour, Christophe Lurquin, Catie Traversari, Vincent Stroobant, Guy R. Cornelis, Thierry Boon-Falleur, Pierre van der Bruggen, Erwin Schultz, Guy Warnier
  • MAGE-A4 antigenic peptides and uses thereof
    Publication number: 20040033541
    Abstract: The invention provides antigenic peptides derived from MAGE polypeptides and presented by HLA-B37 molecules. Methods for diagnosis and treatment which involve the polypeptides also are provided.
    Type: Application
    Filed: August 13, 2002
    Publication date: February 19, 2004
    Inventors: Yi Zhang, Vincent Stroobant, Vincenzo Russo, Thierry Boon-Falleur, Pierre van der Bruggen
  • Isolated peptides derived from mage tumor rejection antigen precursors which complex with HLA-A2 molecules
    Patent number: 6682731
    Abstract: Complexes of SEQ ID NO: 12 and HLA-A2 can be used to generate CTLs. They can be supplemented with IL-6 and IL-12.
    Type: Grant
    Filed: March 23, 2000
    Date of Patent: January 27, 2004
    Assignees: Ludwig Institute for Cancer Research, The Chancellor Masters & Scholars of the University of Oxford, University of Leiden
    Inventors: Alan Townsend, Judy Bastin, Thierry Boon-Falleur, Pierre Van Der Bruggen, Pierre Coulie, Thomas Gajewski, Cornelis J. M. Melief, Marjan J. W. Visseren, Martin W. Kast
  • METHOD FOR IDENTIFYING INDIVIDUALS SUFFERING FROM A CELLULAR ABNORMALITY SOME OF WHOSE ABNORMAL CELLS PRESENT COMPLEXES OF HLA-CW 1601/MAGE-1 DERIVED PEPTIDES, AND METHODS FOR TREATING SAID INDIVIDUALS
    Patent number: 6680056
    Abstract: Peptides which satisfy the formula of SEQ ID NO: 10 bind to HLA-Cw*1601 molecules, and stimulate proliferation of cytolytic T cells. Examples of such peptides are those set forth in SEQ ID NOS: 4 and 5.
    Type: Grant
    Filed: August 8, 2000
    Date of Patent: January 20, 2004
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pierre van der Bruggen, Jean-Pierre Szikora, Pierre Coulie, Claude Wildmann, Pascale Boël, Thierry Boon-Falleur
  • Isolated peptides which bind to HLA-Cw6 molecules and uses thereof
    Publication number: 20030228308
    Abstract: A peptide, previously identified as a binding partner of HLA-Cw3 and Cw16, has now been found to bind to HLA-Cw6. The therapeutic and diagnostic ramifications of this are the subject of this invention, as are various products obtained in the course of the development of the invention.
    Type: Application
    Filed: June 5, 2002
    Publication date: December 11, 2003
    Inventors: Yi Zhang, Catia Traversari, Thierry Boon-Falleur, Pierre Van der Bruggen
  • Isolated peptides which bind to HLA-B18 molecules and uses thereof
    Publication number: 20030228325
    Abstract: A peptide, previously identified as a binding partner of HLA-B44, has now been found to bind to HLA-B18 forming a T cell epitope. The therapeutic and diagnostic ramifications of this are the subject of this invention, as are various products obtained in the course of the development of the invention.
    Type: Application
    Filed: June 5, 2002
    Publication date: December 11, 2003
    Inventors: Janine Bilsborough, Erwin Schultz, Christophe Panichelli, Thierry Boon-Falleur, Pierre Van der Bruggen
  • Method for treating subjects by using BAGE tumor rejection antigen precursors or tumor rejection antigens
    Patent number: 6638512
    Abstract: A family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as BAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as BAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigen precursor molecules are described.
    Type: Grant
    Filed: August 25, 1999
    Date of Patent: October 28, 2003
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pascale Bo{haeck over (e)}l, Claude Wildmann, Thierry Boon-Falleur, Pierre van der Bruggen, Pierre Coulie, Jean-Christophe Renauld
  • MAGE-3 peptides presented by HLA class ll molecules
    Publication number: 20030170792
    Abstract: The invention describes HLA class II binding peptides encoded by the MAGE-3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-3 gene.
    Type: Application
    Filed: June 12, 2002
    Publication date: September 11, 2003
    Inventors: Pascal Chaux, Vincent Stroobant, Thierry Boon-Falleur, Pierre van der Bruggen, Kris Thielemans, Jurgen Corthals
  • Isolated molecules which complex with HLA-Cw*16 molecules, and uses thereof
    Publication number: 20030166837
    Abstract: The invention involves the identification of peptides which complex with HLA-Cw*16 molecules, and which may then provoke lysis of the cells to which they bind, by cytolytic T cells. Diagnostic and therapeutic uses are described.
    Type: Application
    Filed: May 23, 2002
    Publication date: September 4, 2003
    Inventors: Pierre van der Bruggen, Etienne DePlaen, Thierry Boon-Falleur
  • Method for determining BAGE expression
    Publication number: 20030138854
    Abstract: A family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as BAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as BAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigen precursor molecules are described.
    Type: Application
    Filed: February 20, 2002
    Publication date: July 24, 2003
    Inventors: Pascale Boel, Claude Wildmann, Thierry Boon-Falleur, Pierre van der Bruggen, Pierre Coulie, Jean-Christophe Renauld
  • MAGE-A3 peptides presented by HLA class II molecules
    Publication number: 20030049723
    Abstract: The invention describes HLA class II binding peptides encoded by the MAGE-A3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-A3 gene.
    Type: Application
    Filed: May 18, 2001
    Publication date: March 13, 2003
    Inventors: Yi Zhang, Pascal Chaux, Thierry Boon-Falleur, Pierre van der Bruggen
  • Tumor antigens and CTL clones isolated by a novel procedure
    Patent number: 6531451
    Abstract: The present invention relates to isolation of cytotoxic T lymphocyte (CTL) clones. In particular, the present invention relates to isolated CTL clones that are specific for MAGE-1 and MAGE-4, respectively. The CTL clones of the present invention have been isolated by successive steps of stimulation and testing of lymphocytes with antigen presenting cells which present antigens derived from different expression systems, e.g., from recombinant Yersinia, recombinant Salmonella, or recombinant viruses. The present invention further relates to the MAGE-1 and MAGE-4 antigenic peptides as well as the peptide/HLA complexes which are recognized by the isolated CTL clones.
    Type: Grant
    Filed: April 9, 1999
    Date of Patent: March 11, 2003
    Assignees: Ludwig Institute for Cancer Research, Universite Catholique de Louvain
    Inventors: Pascal Chaux, Rosalie Luiten, Nathalie Demotte, Marie-Therese Duffour, Christophe Lurquin, Catia Traversari, Vincent Stroobant, Guy Cornelis, Thiery Boon-Falleur, Pierre van der Bruggen
  • Method for treating cancer by administering MAGE-derived peptides
    Patent number: 6488932
    Abstract: The invention involves the reception of particular nonapeptides by HLA molecules. The nonapeptides are derived from expression products of the MAGE gene family. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.
    Type: Grant
    Filed: December 12, 1995
    Date of Patent: December 3, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon, Pierre van der Bruggen, Etienne De Plaen, Christophe Lurquin, Catia Traversari
  • MAGE antigenic peptides which bind HLA-B35 and HLA-B44
    Publication number: 20020164654
    Abstract: The invention provides antigenic peptides derived from MAGE-A1 polypeptides and presented by HLA-B35 and HLA-B44 molecules. Antigenic peptides derived from MAGE-A3 polypeptides and presented by HLA-B35 molecules also are provided. Methods for diagnosis and treatment which involve the polypeptides also are provided.
    Type: Application
    Filed: January 19, 2001
    Publication date: November 7, 2002
    Inventors: Rosalie Luiten, Thierry Boon-Falleur, Pierre Van der Bruggen, Vincent Stroobant, Nathalie Demotte, Erwin Schultz
  • Isolated nucleic acid molecule encoding peptides which form complexes with MHC molecules HLA-Cw*1601 and uses thereof
    Patent number: 6465184
    Abstract: A family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as BAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as BAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigen precursor molecules are described.
    Type: Grant
    Filed: November 8, 1999
    Date of Patent: October 15, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pascale Bo{haeck over (e)}l, Claude Wildmann, Thierry Boon-Falleur, Pierre van der Bruggen, Pierre Coulie, Jean-Christophe Renauld